The prevalence and clinical implications of c-kit expression in plasma cell myeloma

Histopathology

Volumn 48, Issue 5, 2006, Pages 529-535

  Pruneri, G ^a,c   Ponzoni, M ^b   Ferreri, A J M ^b   Freschi, M ^b   Tresoldi, M ^b   Baldini, L ^b   Mattioli, M ^b   Agnelli, L ^b   Govi, S ^b   Mancuso, P ^b   Agazzi, A ^b   Bertolini, F ^b   Peccatori, J ^b   Bosari, S ^b   Gianelli, U ^b   Viale, G ^a   Neri, A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

c kit; Gene expression; Immunohistochemistry; Plasma cell myeloma; Prognosis

Indexed keywords

ANTHRACYCLINE; BENCE JONES PROTEIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MELPHALAN; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CARCINOGENESIS; CELL DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RNA ISOLATION; THROMBOCYTOPENIA; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; SYNDECANS;

EID: 33645392239     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02375.x     Document Type: Article

References (20)

1. Ullrich A Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990 61 203 212.
2. Heinrich MC Blanke CD Druker BJ Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002 20 1692 1703.
3. Ocqueteau M Orfao A Garcia-Sanz R Almeida J Gonzalez M San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br. J. Haematol. 1994 95 489 493.
4. Garcia-Sanz R Orfao A Gonzalez M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999 93 1032 1037.
5. Potti A Ganti AK Koch M Levitt R Mehdi SA. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. Leuk. Lymphoma 2002 43 2427 2430.
6. Lugli A Went P Khanlari B Nikolova Z Dirnhofer S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch. 2004 444 264 268.
7. Fabris S Storlazzi CT Baldini L et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosomes Cancer 2003 37 261 269.
8. Pruneri G Carboni N Baldini L et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum. Pathol. 2003 34 41 47.
9. Klein U Tu Y Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 2001 194 1625 1638.
10. Mattioli M Agnelli L Fabris S et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005 24 2461 2473.
11. Pruneri G Ponzoni M Ferreri AJM et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol. 2002 118 817 820.
12. Hans CP Weisenburger DD Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282.
13. Lemoli RM Fortuna A Grande A et al. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. Br. J. Haematol. 1994 88 760 769.
14. Bertolini F Mancuso P Gobbi A Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp. Hematol. 2000 28 993 1000.
15. Kuehl WM Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2002 2 175 187.
16. Hornick JL Fletcher CDM. Validating immunohistochemical staining for KIT (CD117). Am. J. Clin. Pathol. 2003 119 325 327.
17. Scotlandi K Manara MC Strammiello R et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J. Clin. Oncol. 2003 21 1952 1960.
18. Wang WL Healy ME Sattler M et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000 19 3521 3528.
19. Lin B Podar K Gupta D et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 62 5019 5026.
20. Pandiella A Carvajal-Vergara X Tabera S Mateo G Gutierrez N San Miguel JF. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br. J. Haematol. 2003 123 858 868.